The "EXTEND" Study: A Randomized, Double-Blind, Parallel-Group, Phase III b, Multi-Centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergoing Elective Hip Replacement or Hip Fracture Surgery

Trial Profile

The "EXTEND" Study: A Randomized, Double-Blind, Parallel-Group, Phase III b, Multi-Centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergoing Elective Hip Replacement or Hip Fracture Surgery

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Enoxaparin sodium; Melagatran; Ximelagatran
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms EXTEND
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Mar 2009 Safety results published in Thrombosis Research.
    • 26 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top